Related Experiment Videos
[Malignant cervical adenopathies of unknown origin]
M J Martínez Martínez1, L Ayala Martínez, J M Ruiz Gómez
1Hospital Clínico Universitario San Cecilio, Universidad de Granada.
Acta Otorrinolaringologica Espanola
|June 1, 1997
Summary
Malignant cervical lymph node enlargement of unknown origin has a poor prognosis, with limited success from combined treatments. Further research is needed for improved diagnostic and therapeutic strategies for this challenging condition.
Area of Science:
- Oncology
- Otolaryngology
- Pathology
Context:
- Retrospective analysis of 26 cases (1985-1995) of malignant cervical lymph node enlargement of unknown primary origin.
- Investigated the diagnostic yield of Ear, Nose, and Throat (ENT) evaluations and disease progression.
- Assessed outcomes following multimodal treatment including surgery, chemotherapy, and radiation therapy.
Purpose:
- To evaluate the outcomes of patients with malignant cervical lymph node enlargement of unknown primary origin.
- To review current literature for advanced diagnostic and therapeutic modalities.
- To identify potential areas for improving patient survival rates.
Summary:
- A retrospective study identified 26 cases of malignant cervical lymph node enlargement. The primary tumor was identified in only 11 cases (8 initially, 3 later); 15 cases remained of unknown origin.
- Patients received combined treatment (surgery, chemotherapy, radiation), but survival was poor, with only 2 patients surviving long-term (6.5 years and 20 months).
- Literature review highlighted the need for novel diagnostic and therapeutic approaches.
Impact:
- This study underscores the poor prognosis associated with unknown primary malignant cervical lymphadenopathy.
- Highlights the limitations of current diagnostic and treatment strategies.
- Emphasizes the critical need for advancements in identifying primary tumors and developing more effective therapies for improved patient outcomes.